Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals

The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc intensification for 48 weeks, and were monitored up to week 60. PBMC an...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2014-01, Vol.9 (1), p.e87334-e87334
Main Authors: Kawana-Tachikawa, Ai, Llibre, Josep M, Bravo, Isabel, Escrig, Roser, Mothe, Beatriz, Puig, Jordi, Puertas, Maria C, Martinez-Picado, Javier, Blanco, Julia, Manzardo, Christian, Miro, Jose M, Iwamoto, Aikichi, Pozniak, Anton L, Gatell, Jose M, Clotet, Bonaventura, Brander, Christian
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
AIDS
Amplification
Analysis
Anti-Retroviral Agents - pharmacology
Antiretroviral agents
Antiretrovirals
CD8 antigen
Clinical trials
Cyclohexanes - pharmacology
Cytokines
Cytokines - analysis
Cèl·lules T
Effector cells
Enzyme-linked immunosorbent assay
Enzyme-Linked Immunospot Assay
Flow Cytometry
Genètica molecular
HIV
HIV (Viruses)
HIV Infections - immunology
HIV-1
Hospitals
Human immunodeficiency virus
Humans
Immune response
Immunity
Immunity, Cellular - drug effects
Infections
Infectious diseases
Influenza
Ligands
Lymphocytes
Lymphocytes T
Maintenance
Medicine
Molecular genetics
Peripheral blood mononuclear cells
Proteomes
Receptors, CCR5 - metabolism
Resposta immunitària
Statistics, Nonparametric
T cell receptors
T cells
T-Lymphocytes - drug effects
T-Lymphocytes - immunology
Triazoles - pharmacology
VIH (Virus)
Viral infections
Virus Internalization - drug effects
Viruses
West Nile virus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc intensification for 48 weeks, and were monitored up to week 60. PBMC and in vitro-expanded T cells were tested for responses to the entire HIV proteome by ELISpot analyses. Intracellular cytokine staining assays were conducted to monitor the (poly)-functionality of HIV-1-specific T cells. Analyses were performed at baseline and week 24 after treatment start, and at week 60 (3 months after maraviroc discontinuation). Maraviroc intensification was associated with a slower decay of virus-specific T cell responses over time compared to the non-intensified regimen in both direct ex-vivo as well as in in-vitro expanded cells. The effector function profiles of virus-specific CD8⁺ T cells were indistinguishable between the two arms and did not change over time between the groups. Maraviroc did not negatively impact any of the measured parameters, but was rather associated with a prolonged maintenance of HIV-1-specific T cell responses. Maraviroc, in addition to its original effect as viral entry inhibitor, may provide an additional benefit on the maintenance of virus-specific T cells which may be especially important for future viral eradication strategies.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0087334